Clinical trials: Prostate Cancer Stage
Prostate Cancer, Rising Prostate Specific Antigen (PSA)
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer
- Trial name
- NCT02796898
- Testing
- SM88 (Cohort 1), SM88 (Cohort 2)
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Tyme, Inc
Recurrent Prostate Cancer
CyberKnife Radiosurgery for Locally Recurrent Prostate CA
The purpose of this study is to scientifically evaluate the effects (good and bad) of a new type of radiation treatment in patients with locally recurrent prostate cancer after prior radiotherapy.
- Trial name
- NCT00851916
- Testing
- CyberKnife Radiosurgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CyberKnife Centers of San Diego
Cancer
Hypofractionated Stereotactic Boost in Prostate Cancer
hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).
- Trial name
- CKNO-PRO (NCT01596816)
- Testing
- First part of treatment : Conformal irradiation, Fiducials placement, Second part : hypofractionated stereotactic boost
- Where
- 7 sites in France
- Volunteers
- 76 people
- Sponsor
- Centre Oscar Lambret
CLL, Solid Tumor, Adult
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
The goal of this clinical trial is to test the safety and preliminary efficacy of a new drug, KLS-1, in adults with different types of solid tumors and chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06506643
- Testing
- Zinc-64 Aspartate
- Where
- 2 sites in Ukraine
- Volunteers
- 36 people
- Sponsor
- Vector Vitale LLC
Prostate Cancer Patients
The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
- Trial name
- NCT04676035
- Testing
- Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This randomized phase II trial studies how well docetaxel and prednisone with or without vaccine therapy works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body.
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01145508
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Prednisone
- Where
- 14 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination.
- Trial name
- NCT03934840
- Testing
- Cabazitaxel, Carboplatin, Abiraterone
- Where
- 8 sites in United States
- Volunteers
- 61 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hormone-refractory Prostate Cancer
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
This study is a phase I study of a cell based prostate cancer therapy, Autologous Lymphoid Effector Cells Specific Against Tumor-cells (ALECSAT).
- Trial name
- ALECSAT (NCT01422850)
- Testing
- ALECSAT
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- CytoVac A/S
Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Genetic Testing for Men With Metastatic Prostate Cancer
This research study provides genetic testing to men with prostate cancer that has spread to other parts of the body (metastatic prostate cancer) and will look for inherited genetic mutations in about 30 cancer-risk genes.
- Conditions
- Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Trial name
- GENTleMEN (NCT03503097)
- Testing
- Biospecimen Collection, Genetic Counseling, Genetic Testing
- Where
- United States
- Volunteers
- 799 people
- Sponsor
- University of Washington
Prostate Cancer
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
This research study is being offered to those patients who have received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable despite having received at…
- Trial name
- NCT03777982
- Testing
- Prednisone, Apalutamide, Abiraterone Acetate
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with…
- Trial name
- NCT00314782
- Testing
- ZD4054 (Zibotentan), Docetaxel
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and androgen receptor pathway inhibitor (ARPI) therapy work in participants with prostate gland cancer which has spread to the bone and…
- Trial name
- RADIANT (NCT04597125)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), ARPI therapy
- Where
- 117 sites in Australia, Austria and 17 more
- Volunteers
- 654 people
- Sponsor
- Bayer
Prostatic Neoplasms
Testing Decision Aids About Early Stage Prostate Cancer
This is an educational intervention study testing the effects of decision aids in promoting patient participation in early stage prostate cancer treatment decision making.
- Trial name
- NCT02053389
- Testing
- DVD Decision Aid, Written decision aid
- Where
- United States
- Volunteers
- 564 people
- Sponsor
- University of Michigan
Prostate Cancer
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00589420
- Testing
- docetaxel, sorafenib tosylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.
A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA <0.70 ng/ml)…
- Trial name
- PROPER2 (NCT04858880)
- Testing
- Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
- Where
- 3 sites in Sweden
- Volunteers
- 374 people
- Sponsor
- Lund University Hospital
Recurrent Prostate Cancer, Stage I Prostate Cancer
Cilengitide in Treating Patients With Prostate Cancer
This phase II trial is studying how well cilengitide works in treating patients with prostate cancer. Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00121238
- Testing
- cilengitide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
The study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with low or intermediate-risk prostate cancer.
- Trial name
- FORT (NCT04984343)
- Testing
- Radiation Therapy
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who…
- Trial name
- NCT02445976
- Testing
- Seviteronel: given orally once daily in 28-day cycles
- Where
- 21 sites in United States
- Volunteers
- 197 people
- Sponsor
- Innocrin Pharmaceutical
Prostate Cancer
[18F]PSMA-11 PET/CT Phase 3 Clinical Study
Prostate cancer (PCa) is the most frequently occurring male cancer in Belgium. After treatment with surgery and/or radiotherapy, almost half of the patients suffer from a tumor recurrence, often diagnosed by an increase in serum…
- Trial name
- NGP3 (NCT03911310)
- Testing
- [18F]PSMA-11, [68Ga]PSMA-11
- Where
- Belgium
- Volunteers
- 96 people
- Sponsor
- University Hospital, Ghent
Prostate Cancer, Sexual Dysfunction and Infertility
Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Male hormones can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones.
- Trial name
- NCT00003323
- Testing
- finasteride, flutamide, quality-of-life assessment
- Where
- 43 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.